Faeth Therapeutics Grants Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Stock Options Granted: Faeth Therapeutics has granted stock options totaling 180,350 shares to six new employees as a significant inducement for their employment, highlighting the company's commitment to attracting talent.
- Option Details: Of these, options for 157,850 shares will be effective on June 25, 2026, with an exercise price of $24.67 per share, while options for 22,500 shares will be effective on June 29, 2026, priced at $23.22 per share, both equal to the closing price on the grant date.
- Vesting Schedule: The granted options will vest 25% on the first anniversary of each employee's start date, with the remaining shares vesting in 36 equal monthly installments thereafter, ensuring continued employee service with Faeth.
- Company Overview: Faeth Therapeutics focuses on improving cancer treatment outcomes through multi-node inhibition of critical oncogenic pathways, with its lead program PIKTOR under development for endometrial and breast cancer, showcasing the company's innovative potential in the biotech sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FTH
Wall Street analysts forecast FTH stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 23.660
Low
Averages
High
Current: 23.660
Low
Averages
High
About FTH
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faeth Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: Faeth Therapeutics has granted stock options totaling 180,350 shares to six new employees as a significant inducement for their employment, highlighting the company's commitment to attracting talent.
- Option Details: Of these, options for 157,850 shares will be effective on June 25, 2026, with an exercise price of $24.67 per share, while options for 22,500 shares will be effective on June 29, 2026, priced at $23.22 per share, both equal to the closing price on the grant date.
- Vesting Schedule: The granted options will vest 25% on the first anniversary of each employee's start date, with the remaining shares vesting in 36 equal monthly installments thereafter, ensuring continued employee service with Faeth.
- Company Overview: Faeth Therapeutics focuses on improving cancer treatment outcomes through multi-node inhibition of critical oncogenic pathways, with its lead program PIKTOR under development for endometrial and breast cancer, showcasing the company's innovative potential in the biotech sector.
See More
Major Wall Street Rating Changes on Friday
- Diageo Upgrade: TD Cowen upgraded Diageo from hold to buy, citing valuation dislocation as an attractive entry point, with CEO-led cost cuts and reinvestment expected to restore growth and enhance commercial execution.
- James Hardie Initiation: Stephens initiated coverage of James Hardie with an overweight rating and a $31 price target, highlighting its status as a high-quality company and its position as the second-largest composite decking manufacturer following its merger with AZEK.
- Nike Downgrade: KeyBanc downgraded Nike from overweight to sector weight, indicating that the turnaround is taking longer than anticipated, with slight reductions in FY27 estimates reflecting higher-than-expected headwinds in China and EMEA.
- American Tower Upgrade: RBC upgraded American Tower from sector perform to outperform, noting superior organic revenue growth compared to peers, despite rising interest rate pressures, indicating strong market potential.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
Faeth Therapeutics Grants Stock Options to New Employees
- Stock Options Granted: Faeth Therapeutics has granted stock options totaling 180,350 shares to six new employees as a significant inducement for their employment, highlighting the company's commitment to attracting talent.
- Option Details: Of these, options for 157,850 shares will be effective on June 25, 2026, with an exercise price of $24.67 per share, while options for 22,500 shares will be effective on June 29, 2026, priced at $23.22 per share, both equal to the closing price on the grant date.
- Vesting Schedule: The granted options will vest 25% on the first anniversary of each employee's start date, with the remaining shares vesting in 36 equal monthly installments thereafter, ensuring continued employee service with Faeth.
- Company Overview: Faeth Therapeutics focuses on improving cancer treatment outcomes through multi-node inhibition of critical oncogenic pathways, with its lead program PIKTOR under development for endometrial and breast cancer, showcasing the company's innovative potential in the biotech sector.
See More
Major Wall Street Rating Changes on Friday
- Diageo Upgrade: TD Cowen upgraded Diageo from hold to buy, citing valuation dislocation as an attractive entry point, with CEO-led cost cuts and reinvestment expected to restore growth and enhance commercial execution.
- James Hardie Initiation: Stephens initiated coverage of James Hardie with an overweight rating and a $31 price target, highlighting its status as a high-quality company and its position as the second-largest composite decking manufacturer following its merger with AZEK.
- Nike Downgrade: KeyBanc downgraded Nike from overweight to sector weight, indicating that the turnaround is taking longer than anticipated, with slight reductions in FY27 estimates reflecting higher-than-expected headwinds in China and EMEA.
- American Tower Upgrade: RBC upgraded American Tower from sector perform to outperform, noting superior organic revenue growth compared to peers, despite rising interest rate pressures, indicating strong market potential.
See More
Tenon Files S-1, Stock Surges 77.57%
- Tenon Stock Offering: Tenon Medical Inc. (TNON) filed a Form S-1 to offer up to 1.81 million shares and 6.98 million warrants at a public offering price of $0.6021 per unit, with potential proceeds aimed at bolstering future growth, especially if a reverse stock split occurs, increasing warrant exercise shares to 8.72 million.
- Azitra's Strategic Shift: Azitra Inc. (AZTR) outlined its 2026 roadmap in a shareholder letter, focusing on the ATR-COSF program for the cosmetic market, with clinical studies expected to start by late 2026, positioning the company for potential commercialization by 2027, enhancing its competitive edge in precision dermatology.
- Nuvectis Licensing Deal: Nuvectis Pharma Inc. (NVCT) announced a strategic licensing agreement with Haisco Pharmaceutical Group for exclusive ex-China rights to two clinical-stage compounds, NXP100 and NXP200, which could open new market opportunities in treating complement-mediated diseases and BRAF mutations.
- REGENXBIO's FDA Alignment: REGENXBIO Inc. (RGNX) has aligned with the FDA for the resubmission of its Biologics License Application for NAVSUNLI, with the FDA acknowledging existing clinical data sufficiency for accelerated approval, anticipating resubmission in Q3 2026, which could significantly impact the company's market position in gene therapy for Hunter syndrome.
See More
